Young lives are being saved thanks to the Human Papillomavirus (HPV) vaccine, with a new study showing that children who receive it at 12 or 13 have almost zero risk of dying from cervical cancer before reaching their thirties. This groundbreaking research highlights the profound impact of the HPV immunisation programme in preventing a life-threatening disease.
The study reinforces the long-term effectiveness of the vaccine, which has been offered to young people in the UK for over a decade. Cervical cancer is predominantly caused by persistent infection with certain types of HPV – a very common group of viruses found in many people without causing harm. The vaccine works by protecting against the types of HPV that cause most cervical cancers, as well as some other cancers of the genital area, anus, mouth, and throat.
In the UK, the NHS offers the HPV vaccine to all children in school year 8, typically aged 12 to 13. Initially introduced for girls in 2008, it was extended to boys in 2019, as evidence showed that HPV can cause a range of cancers in both sexes. The vaccination is delivered as a single dose for most individuals under 25, following a change in the schedule from two doses – based on evidence suggesting comparable protection.
The implications of this research are substantial for public health. By significantly reducing the risk of premature death from cervical cancer, the vaccine not only saves lives but also alleviates the immense personal and societal burden associated with cancer diagnosis and treatment at a young age. This evidence further strengthens the case for continued high uptake of the HPV vaccine.
While the vaccine offers substantial protection, it is crucial for individuals to remember that it does not protect against all types of HPV that can cause cancer. Therefore, regular cervical screening – also known as smear tests – remains a vital tool for early detection and prevention for women and people with a cervix from age 25. Screening can identify abnormal cell changes before they develop into cancer, allowing for timely intervention.
Healthcare professionals consistently advise that anyone eligible for the HPV vaccine should take it, and those eligible for cervical screening should attend their appointments. For specific medical advice, individuals should consult their GP or call NHS 111.
Source: Study findings (details omitted as per instruction)